Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry

Dr Manish Saxena


Clinical Co-Director, William Harvey Clinical Research Centre and Deputy Director Research, Barts Health NHS Trust and QMUL

Centre: Clinical Pharmacology and Precision Medicine, Clinical Research Centre

Telephone: +44(0) 20 7882 3856
Twitter: @DrManishNSaxena


Dr Saxena completed MBBS in 1996 and has been practising medicine for over 25 years. He completed a Master’s degree in Health Care Research and Clinical Drug Development with distinction from Queen Mary University of London. He is Deputy Director for Research for Barts Health NHS Trust/QMUL and Clinical Co-Director at the William Harvey Clinical Research Centre. He works at Barts Hypertension Clinic as a European Accredited specialist in hypertension. Dr Saxena has worked with the Health Research Authority as an expert member for over 12 years and has been chair of the National Research ethics committee for over 7 years. He is part of the National Institute for Health and Care Research (NIHR) leadership group as Speciality Research Lead for Diabetes for North Thames CRN. He is Academic Lead for Innovation and Commercial Partnerships for Barts Faculty of Medicine.


Group members 

Armida Balawon, Ania Michalska, Francis Galera, Benildo Quiros, Aaron Jairo Oblena, Arooj Ayub, Brenda Roberts, Rizwana Ayub


Dr Saxena is a cardiovascular (CV) physician passionate about developing novel therapies for CV prevention and treatment. As UK Chief Investigator and Barts lead, he leads on several studies in high-risk patients with dyslipidaemia (with second generation PCSK9i such as Inclisiran and oral PCSK9i, Bempedoic Acid, CETP modulators); in T2DM and CHF (SGLT2i, GLP-1, Aldose reductase inhibitors). He runs studies in Hypertension pioneering pharmacotherapy (SiRNA) and novel device therapies such as Renal Denervation, Carotid sinus modulation and Arterio-venous coupler besides collaborating on novel BP monitoring technologies such as Life light using remote PPG technology. He also works with patients with autonomic dysfunction and has run studies in patients with neurogenic orthostatic hypotension. His work also includes studies in other CV therapeutics involving anti-platelets, new oral anti-coagulants, dementia prevention and treatment.

Memberships and awards

  • Member European Society of HTN
  • Member European Society of Cardiology
  • Member Joint British and Irish Hypertension Society

Key Publications

  • Saxena M, Schmieder RE, Kirtane AJ, Mahfoud F, Daemen J, Basile J, Lurz P, Gosse P et al. ( 2022 ) . Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. Journal of Human Hypertension vol. 36, ( 7 ) 629 - 639.
  • REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, et al. ( 2022 ). Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA vol. 327 , ( 13 ) 1247 - 1259.
  • Fisher NDL, Kirtane AJ, Daemen J, Rader F, Lobo MD, Saxena M, Abraham J, Schmieder RE et al. ( 2022 ). Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. Journal of Hypertension vol. 40, ( 2 ) 221 - 228.
  • Asselbergs FW, Linschoten M, Uijl A, Schut A, Jakob CEM, Romão LR, Bell RM, McFarlane E et al. ( 2022 ) Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. European Heart Journal vol. 43, (11) 1104 - 1120.
  • Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wilkins R, Jin J, Chen C et al. ( 2022 ) . Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program. PACE - Pacing and Clinical Electrophysiology vol. 45, ( 1 ) 83 - 91.
  • Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Jin J, Laeis P, Wilkins R et al. ( 2021 ) . Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study (BMC Cardiovascular Disorders, (2020), 20, 1, (504), 10.1186/s12872-020-01766-w). BMC Cardiovascular Disorders vol. 21, ( 1 ).
  • Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T, et al. ( 2021 ). Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. vol. 78, B152 - B152.
  • von Heymann C, Unverdorben M, Colonna P, Ortiz AS, Saxena M, Vanassche T, Weitz JI, Wilkins R et al. ( 2021 ) . Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. Blood vol. 138, ( Supplement 1 ) 3024 - 3024.
  • Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T, et al. ( 2021 ). TCT-369 Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial. Journal of the American College of Cardiology vol. 78, ( 19 ).
  • Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A et al. ( 2021 ) . Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. The Lancet vol. 397, ( 10293 ) 2476 - 2486.
  • Bertog S, Sharma A, Mahfoud F, Pathak A, Schmieder RE, Sievert K, Papademetriou V, Weber MA et al. ( 2021 ) . Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter. Cardiovascular Revascularization Medicine vol. 24 , 77 - 86.
  • Gosse P, Cremer A, Kirtane AJ, Lobo MD, Saxena M, Daemen J, Wang Y, Stegbauer J et al. ( 2021 ) . Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study. Hypertension vol. 77 , ( 2 ) 529 - 536.
  • Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, Wang Y, Saxena M et al. ( 2020 ) . 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC: Cardiovascular Interventions vol. 13 , ( 24 ) 2922 - 2933.
  • Feyz L, Wang Y, Pathak A, Saxena M, Mahfoud F, Sanghvi K, Peterson R, Kirtane AJ, et al. ( 2020 ). Using social media to recruit study participants for a randomized trial for hypertension. European Heart Journal - Digital Health vol. 1, ( 1 ) 71 - 74.
  • Saxena M, Kermali M, Balawon A, Pheby J, Benu E, Piniera B, Low D, Mathur A et al. ( 2020 ) . Collateral benefits of participation in clinical research: insights from a resistant hypertension trial screen out population. JOURNAL OF HUMAN HYPERTENSION. vol. 34,
  • Colonna P, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wolpert D, Laeis P, Wilkins R et al. ( 2020 ) . Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study. Clinical Cardiology vol. 43, ( 7 ) 769 - 780.
  • Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, Sharp ASP, Bloch MJ et al. ( 2019 ) . Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation vol. 139, ( 22 ) 2542 - 2553.
  • McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, et al. ( 2019 ). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation vol. 139, ( 3 ) 351 - 361.
  • Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M et al. ( 2019 ) . Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA vol. 321 , ( 1 ) 69 - 79.
  • Lobo MD, Sharp ASP, Kapil V, Davies J, De Belder MA, Cleveland T, Bent C, Chapman N, et al. ( 2019 ). Joint UK societies' 2019 consensus statement on renal denervation. Heart.
  • Sharp ASP, Saxena M, Lobo MD ( 2018 ) . Renal artery sympathetic denervation: Back on track!. European Heart Journal vol. 39, ( 46 ) 4056 - 4057.
  • Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, Faconti L, Glover M, et al. ( 2018 ). A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. American Heart Journal vol. 204, 102 - 108.
  • Saxena M, Shour T, Shah M, Wolff CB, Julu POO, Kapil V, Collier DJ, Ng FL et al. ( 2018 ) . Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. J Am Heart Assoc vol. 7, ( 12 )
  • Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ et al. ( 2018 ) . Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. The Lancet vol. 391, ( 10137 ) 2335 - 2345.
  • Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK et al. ( 2018 ). Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. The Lancet Diabetes and Endocrinology vol. 6, ( 6 ) 464 - 475.
  • BROWN MJ ( 2018 ). Investigation of the endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms study. Lancet Diabetes and Endocrinology vol. 6, ( 6 ) 464 - 475.
  • Schmieder RE, Ott C, Toennes SW, Bramlage P, Gertner M, Dawood O, Baumgart P, O'Brien B et al. ( 2018 ) . Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension-WAVE IV. Journal of Hypertension. vol. 36, 680 - 689.
  • Saxena M, Shour T, Shah M, Wolff C, Collier DJ, Kapil V, Balawon A, Pheby JM et al. ( 2017 ) . Attenuation of splanchnic autotransfusion following non-invasive ultrasound renal denervation: a novel marker of procedural success. JOURNAL OF HUMAN HYPERTENSION. vol. 31, 679 - 680.
  • Schmieder RE, Ott C, Toennes S, Gertner M, Dawood O, Saxena M, O’Brien B, Lobo M ( 2017 ) . [LB.01.02] PHASE II RANDOMIZED SHAM-CONTROLLED STUDY OF RENAL DENERVATION FOR SUBJECTS WITH UNCONTROLLED HYPERTENSION – WAVE IV. Journal of Hypertension. vol. 35,
  • Lobo MD, Ott C, Sobotka PA, Saxena M, Stanton A, Cockcroft JR, Sulke N, Dolan E et al. ( 2017 ). Central iliac arteriovenous anastomosis for uncontrolled hypertension: One-year results from the ROX CONTROL HTN trial. Hypertension vol. 70, ( 6 ) 1099 - 1105 .
  • Floyd CN, Adeel MY, Wolff CB, Julu P, Shah M, Collier DJ, Saxena M, Brier T et al. ( 2016 ) . First-in-man treatment of severe blood pressure variability with baroreflex activation therapy. International Journal of Cardiology vol. 220, Article C, 577 - 579.
  • Ng FL, Saxena M, Mahfoud F, Pathak A, Lobo MD ( 2016 ) . Device-based Therapy for Hypertension. Curr Hypertens Rep vol. 18 , ( 8 ) 61 - 61.
  • Burchell AE, Chan K, Ratcliffe LEK, Hart EC, Saxena M, Collier DJ, Jain AK, Mathur A, et al. ( 2016 ). Controversies Surrounding Renal Denervation: Lessons Learned From Real-World Experience in Two United Kingdom Centers. Journal of Clinical Hypertension vol. 18, ( 6 ) 585 - 592.
  • De Jager RL, Sanders MF, Bots ML, Lobo MD, Ewen S, Beeftink MMA, Böhm M, Daemen J et al. ( 2016 ). Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clinical Research in Cardiology vol. 105, ( 9 ) 755 - 762.
  • Saxena M, Antoniou S, Hamedi N, Robinson P, Singh H, Mukhtar O, Kapil V, Lobo MD ( 2016 ). Multiple drug-intolerant hypertension: A case series utilising a novel-treatment algorithm. British Journal of General Practice vol. 66, ( 645 ) e285 - e287
  • Antoniou S, Saxena M, Hamedi N, de Cates C, Moghul S, Lidder S, Kapil V, Lobo MD ( 2016 ). Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm. Journal of Clinical Hypertension vol. 18, ( 2 ) 129 - 138.
  • Wolff CB, Collier DJ, Shah M, Saxena M, Brier TJ, Kapil V, Green D, Lobo M ( 2016 ). A discussion on the regulation of blood flow and pressure. Advances in Experimental Medicine and Biology vol. 876, 129 - 135.


  • Prof Anoop Chauhan, MBE, Director Research & Innovation, Portsmouth Hospitals NHS Trust
  • Prof Melvin Lobo, Director Barts BP Services
  • Prof Feng He, Prof of Global Health Research, Wolfson Institute
  • Dr David Collier, Deputy Director, Barts CTU
  • Antonio Sotiris, Chief Pharmacist Barts Hospital
  • Oxford Clinical Trials Unit
  • Blood Pressure UK


June 2022

A new jab for patients with high blood pressure could replace daily tablets - Mirror

May 2022

Barts Health Trust held an event for International Clinical Trials Day 2022 - Trials Connect

April 2022

6-month-to-month blood pressure injection could before long substitute a day-to-day pill - Euro News Source

Free from tablets? UK begins trial for biannual injection to treat high blood pressure - Khaleej News

Six-monthly blood strain injection may quickly substitute a every day tablet - Polish News

Why I won't have another lousy night's sleep -Malcolm's story - Blood Pressure UK

Twice-yearly jabs for high blood pressure could replace need to take daily pills - The Telegraph

Barts Health and Queen Mary scientists to trial world-first long-acting injection for high blood pressure - Barts Health NHS Trust

Twice-a-year jab to replace daily blood pills - Express

Twice-yearly jab to lower blood pressure could be offered as an alternative to daily pills by 2025 - Mail Online

World-first jab could treat one of biggest silent killers – replacing daily drugs - The Sun

NHS Trust to trial world’s first high blood pressure injection - National Health Executive 

Medical breakthrough could mean big changes for people with high blood pressure - Planet Radio

Improving access to innovative treatments: A patient centred approach - UCL Partners

Biannual injection could keep blood pressure in check without daily pill - China Daily

December 2021

Lifelight raises $8m to turn devices in self-monitoring platforms - MedTech News

June 2021

Procedure using ultrasound energy found to treat high blood pressure - Eureka alerts

November 2010

Barts trials treatment for high blood pressure with revolutionary potential - Queen Mary University of London

Back to top